Ceres Nanosciences

About:

Ceres Nanosciences Inc.is a privately held life sciences company engaged in the research, development

Website: http://www.ceresnano.com/

Twitter/X: Nanotrap

Top Investors: National Institutes of Health, Bill & Melinda Gates Foundation, Centers for Disease Control and Prevention, GreyBird Ventures, Virginia Catalyst

Description:

Ceres Nanosciences Inc. (“Ceres”) is a privately held life sciences company engaged in the research, development, and commercialization of innovative sample preparation products, based on its proprietary Nanotrap® technology, which captures, enriches and preserves analytes/biomarkers. Early detection of biomarkers, in particular those of low abundance, is key to the diagnosis and treatment of diseases such as cancer, cardiac, and infectious diseases, resulting in improved patient benefit and reduced health care costs. Ceres has a broad product pipeline of advanced sample collection technologies and diagnostics, funded through federal agency grants and industry collaboration funding. Ceres’ lead product in development is a direct antigen test for the diagnosis of Lyme disease, which will be available commercially in 2015.

Total Funding Amount:

$24.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Manassas, Virginia, United States

Founded Date:

2008-01-01

Contact Email:

info(AT)ceresnano.com

Founders:

Emanuel Petricoin, Lance Liotta, Ross Dunlap

Number of Employees:

1-10

Last Funding Date:

2022-09-09

IPO Status:

Private

Industries:

© 2025 bioDAO.ai